PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. Nyström, T., Sartipy, U., Franzén, S., Eliasson, B., Gudbjörnsdottir, S., Miftaraj, M., Lagerqvist, B., Svensson, A., & Holzmann, M. J. Journal of the American College of Cardiology, 2017. ![PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Background It is unknown if coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) may offer a survival benefit in patients with type 1 diabetes (T1D) in need of multivessel revascularization. Objectives This study sought to determine if patients with T1D and multivessel disease may benefit from CABG compared with PCI. Methods In an observational cohort study, the authors included all patients with T1D who underwent a first multivessel revascularization in Sweden from 1995 to 2013. The authors used the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) register, the Swedish National Diabetes Register, and the Swedish National Patient Register to retrieve information about patient characteristics and outcomes. They estimated hazard ratios (HRs) adjusted for confounders with 95% confidence intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction, repeat revascularization, stroke, and heart failure using inverse probability of treatment weighting based on propensity scores. Results In total, 683 patients who underwent CABG and 1,863 patients who underwent PCI were included. During a mean follow-up of 10.6 years, 53% of patients in the CABG group and 45% in the PCI group died. PCI, compared with CABG, was associated with a similar risk of all-cause mortality (HR: 1.14; 95% CI: 0.99 to 1.32), but higher risks of death from coronary heart disease (HR: 1.45; 95% CI: 1.21 to 1.74), myocardial infarction (HR: 1.47; 95% CI: 1.23 to 1.78), and repeat revascularization (HR: 5.64; 95% CI: 4.67 to 6.82). No differences in risks of stroke or heart failure were found. Conclusions Notwithstanding the inclusion of patients with T1D who might not have been able to undergo CABG in the PCI group we found that PCI, compared with CABG, was associated with higher rates and risks of coronary heart disease mortality, myocardial infarction, and repeat revascularizations. Our findings indicate that CABG may be the preferred strategy in patients with T1D in need of multivessel revascularization.
@article{nystrom_pci_2017,
title = {{PCI} {Versus} {CABG} in {Patients} {With} {Type} 1 {Diabetes} and {Multivessel} {Disease}},
issn = {0735-1097},
url = {http://www.sciencedirect.com/science/article/pii/S0735109717388897},
doi = {10.1016/j.jacc.2017.07.744},
abstract = {Background
It is unknown if coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) may offer a survival benefit in patients with type 1 diabetes (T1D) in need of multivessel revascularization.
Objectives
This study sought to determine if patients with T1D and multivessel disease may benefit from CABG compared with PCI.
Methods
In an observational cohort study, the authors included all patients with T1D who underwent a first multivessel revascularization in Sweden from 1995 to 2013. The authors used the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) register, the Swedish National Diabetes Register, and the Swedish National Patient Register to retrieve information about patient characteristics and outcomes. They estimated hazard ratios (HRs) adjusted for confounders with 95\% confidence intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction, repeat revascularization, stroke, and heart failure using inverse probability of treatment weighting based on propensity scores.
Results
In total, 683 patients who underwent CABG and 1,863 patients who underwent PCI were included. During a mean follow-up of 10.6 years, 53\% of patients in the CABG group and 45\% in the PCI group died. PCI, compared with CABG, was associated with a similar risk of all-cause mortality (HR: 1.14; 95\% CI: 0.99 to 1.32), but higher risks of death from coronary heart disease (HR: 1.45; 95\% CI: 1.21 to 1.74), myocardial infarction (HR: 1.47; 95\% CI: 1.23 to 1.78), and repeat revascularization (HR: 5.64; 95\% CI: 4.67 to 6.82). No differences in risks of stroke or heart failure were found.
Conclusions
Notwithstanding the inclusion of patients with T1D who might not have been able to undergo CABG in the PCI group we found that PCI, compared with CABG, was associated with higher rates and risks of coronary heart disease mortality, myocardial infarction, and repeat revascularizations. Our findings indicate that CABG may be the preferred strategy in patients with T1D in need of multivessel revascularization.},
urldate = {2017-08-26TZ},
journal = {Journal of the American College of Cardiology},
author = {Nyström, Thomas and Sartipy, Ulrik and Franzén, Stefan and Eliasson, Björn and Gudbjörnsdottir, Soffia and Miftaraj, Mervete and Lagerqvist, Bo and Svensson, Ann-Marie and Holzmann, Martin J.},
year = {2017},
keywords = {Myocardial Revascularization, Prognosis, Sweden, coronary artery disease}
}
Downloads: 0
{"_id":"ALATdMG8HQLKtDW95","bibbaseid":"nystrm-sartipy-franzn-eliasson-gudbjrnsdottir-miftaraj-lagerqvist-svensson-etal-pciversuscabginpatientswithtype1diabetesandmultivesseldisease-2017","downloads":0,"creationDate":"2017-09-09T10:01:11.210Z","title":"PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease","author_short":["Nyström, T.","Sartipy, U.","Franzén, S.","Eliasson, B.","Gudbjörnsdottir, S.","Miftaraj, M.","Lagerqvist, B.","Svensson, A.","Holzmann, M. J."],"year":2017,"bibtype":"article","biburl":"https://api.zotero.org/users/138800/collections/T3XNBU64/items?key=Dgo7eHao0WH1Z1bvtM1v1uJG&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease","issn":"0735-1097","url":"http://www.sciencedirect.com/science/article/pii/S0735109717388897","doi":"10.1016/j.jacc.2017.07.744","abstract":"Background It is unknown if coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) may offer a survival benefit in patients with type 1 diabetes (T1D) in need of multivessel revascularization. Objectives This study sought to determine if patients with T1D and multivessel disease may benefit from CABG compared with PCI. Methods In an observational cohort study, the authors included all patients with T1D who underwent a first multivessel revascularization in Sweden from 1995 to 2013. The authors used the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) register, the Swedish National Diabetes Register, and the Swedish National Patient Register to retrieve information about patient characteristics and outcomes. They estimated hazard ratios (HRs) adjusted for confounders with 95% confidence intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction, repeat revascularization, stroke, and heart failure using inverse probability of treatment weighting based on propensity scores. Results In total, 683 patients who underwent CABG and 1,863 patients who underwent PCI were included. During a mean follow-up of 10.6 years, 53% of patients in the CABG group and 45% in the PCI group died. PCI, compared with CABG, was associated with a similar risk of all-cause mortality (HR: 1.14; 95% CI: 0.99 to 1.32), but higher risks of death from coronary heart disease (HR: 1.45; 95% CI: 1.21 to 1.74), myocardial infarction (HR: 1.47; 95% CI: 1.23 to 1.78), and repeat revascularization (HR: 5.64; 95% CI: 4.67 to 6.82). No differences in risks of stroke or heart failure were found. Conclusions Notwithstanding the inclusion of patients with T1D who might not have been able to undergo CABG in the PCI group we found that PCI, compared with CABG, was associated with higher rates and risks of coronary heart disease mortality, myocardial infarction, and repeat revascularizations. Our findings indicate that CABG may be the preferred strategy in patients with T1D in need of multivessel revascularization.","urldate":"2017-08-26TZ","journal":"Journal of the American College of Cardiology","author":[{"propositions":[],"lastnames":["Nyström"],"firstnames":["Thomas"],"suffixes":[]},{"propositions":[],"lastnames":["Sartipy"],"firstnames":["Ulrik"],"suffixes":[]},{"propositions":[],"lastnames":["Franzén"],"firstnames":["Stefan"],"suffixes":[]},{"propositions":[],"lastnames":["Eliasson"],"firstnames":["Björn"],"suffixes":[]},{"propositions":[],"lastnames":["Gudbjörnsdottir"],"firstnames":["Soffia"],"suffixes":[]},{"propositions":[],"lastnames":["Miftaraj"],"firstnames":["Mervete"],"suffixes":[]},{"propositions":[],"lastnames":["Lagerqvist"],"firstnames":["Bo"],"suffixes":[]},{"propositions":[],"lastnames":["Svensson"],"firstnames":["Ann-Marie"],"suffixes":[]},{"propositions":[],"lastnames":["Holzmann"],"firstnames":["Martin","J."],"suffixes":[]}],"year":"2017","keywords":"Myocardial Revascularization, Prognosis, Sweden, coronary artery disease","bibtex":"@article{nystrom_pci_2017,\n\ttitle = {{PCI} {Versus} {CABG} in {Patients} {With} {Type} 1 {Diabetes} and {Multivessel} {Disease}},\n\tissn = {0735-1097},\n\turl = {http://www.sciencedirect.com/science/article/pii/S0735109717388897},\n\tdoi = {10.1016/j.jacc.2017.07.744},\n\tabstract = {Background\nIt is unknown if coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) may offer a survival benefit in patients with type 1 diabetes (T1D) in need of multivessel revascularization.\nObjectives\nThis study sought to determine if patients with T1D and multivessel disease may benefit from CABG compared with PCI.\nMethods\nIn an observational cohort study, the authors included all patients with T1D who underwent a first multivessel revascularization in Sweden from 1995 to 2013. The authors used the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) register, the Swedish National Diabetes Register, and the Swedish National Patient Register to retrieve information about patient characteristics and outcomes. They estimated hazard ratios (HRs) adjusted for confounders with 95\\% confidence intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction, repeat revascularization, stroke, and heart failure using inverse probability of treatment weighting based on propensity scores.\nResults\nIn total, 683 patients who underwent CABG and 1,863 patients who underwent PCI were included. During a mean follow-up of 10.6 years, 53\\% of patients in the CABG group and 45\\% in the PCI group died. PCI, compared with CABG, was associated with a similar risk of all-cause mortality (HR: 1.14; 95\\% CI: 0.99 to 1.32), but higher risks of death from coronary heart disease (HR: 1.45; 95\\% CI: 1.21 to 1.74), myocardial infarction (HR: 1.47; 95\\% CI: 1.23 to 1.78), and repeat revascularization (HR: 5.64; 95\\% CI: 4.67 to 6.82). No differences in risks of stroke or heart failure were found.\nConclusions\nNotwithstanding the inclusion of patients with T1D who might not have been able to undergo CABG in the PCI group we found that PCI, compared with CABG, was associated with higher rates and risks of coronary heart disease mortality, myocardial infarction, and repeat revascularizations. Our findings indicate that CABG may be the preferred strategy in patients with T1D in need of multivessel revascularization.},\n\turldate = {2017-08-26TZ},\n\tjournal = {Journal of the American College of Cardiology},\n\tauthor = {Nyström, Thomas and Sartipy, Ulrik and Franzén, Stefan and Eliasson, Björn and Gudbjörnsdottir, Soffia and Miftaraj, Mervete and Lagerqvist, Bo and Svensson, Ann-Marie and Holzmann, Martin J.},\n\tyear = {2017},\n\tkeywords = {Myocardial Revascularization, Prognosis, Sweden, coronary artery disease}\n}\n\n","author_short":["Nyström, T.","Sartipy, U.","Franzén, S.","Eliasson, B.","Gudbjörnsdottir, S.","Miftaraj, M.","Lagerqvist, B.","Svensson, A.","Holzmann, M. J."],"key":"nystrom_pci_2017","id":"nystrom_pci_2017","bibbaseid":"nystrm-sartipy-franzn-eliasson-gudbjrnsdottir-miftaraj-lagerqvist-svensson-etal-pciversuscabginpatientswithtype1diabetesandmultivesseldisease-2017","role":"author","urls":{"Paper":"http://www.sciencedirect.com/science/article/pii/S0735109717388897"},"keyword":["Myocardial Revascularization","Prognosis","Sweden","coronary artery disease"],"downloads":0},"search_terms":["pci","versus","cabg","patients","type","diabetes","multivessel","disease","nyström","sartipy","franzén","eliasson","gudbjörnsdottir","miftaraj","lagerqvist","svensson","holzmann"],"keywords":["myocardial revascularization","prognosis","sweden","coronary artery disease"],"authorIDs":[],"dataSources":["ZtuEJfqHnCQNPwXoW"]}